KR20210137520A - 항-il-36r 항체 제형 - Google Patents

항-il-36r 항체 제형 Download PDF

Info

Publication number
KR20210137520A
KR20210137520A KR1020217032399A KR20217032399A KR20210137520A KR 20210137520 A KR20210137520 A KR 20210137520A KR 1020217032399 A KR1020217032399 A KR 1020217032399A KR 20217032399 A KR20217032399 A KR 20217032399A KR 20210137520 A KR20210137520 A KR 20210137520A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217032399A
Other languages
English (en)
Korean (ko)
Inventor
산드라 니콜 덴킨거
안나 마리아 슈타이너
데릭 스펜서 카타야마
라즈니 프라사드 메라
인고 마이클 프레서
라비자 싱
사라 케이 라이트
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20210137520A publication Critical patent/KR20210137520A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217032399A 2019-03-08 2020-03-05 항-il-36r 항체 제형 Pending KR20210137520A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815405P 2019-03-08 2019-03-08
US62/815,405 2019-03-08
PCT/US2020/021059 WO2020185479A1 (en) 2019-03-08 2020-03-05 Anti-il-36r antibody formulations

Publications (1)

Publication Number Publication Date
KR20210137520A true KR20210137520A (ko) 2021-11-17

Family

ID=70009446

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032399A Pending KR20210137520A (ko) 2019-03-08 2020-03-05 항-il-36r 항체 제형

Country Status (14)

Country Link
US (2) US11730812B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934617A1 (cg-RX-API-DMAC7.html)
JP (2) JP7420827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210137520A (cg-RX-API-DMAC7.html)
CN (1) CN113543772A (cg-RX-API-DMAC7.html)
AU (1) AU2020238676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132917A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002331A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192405A1 (cg-RX-API-DMAC7.html)
IL (1) IL286100B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010783A (cg-RX-API-DMAC7.html)
PH (1) PH12021552150A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020185479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2026041035A1 (zh) * 2024-08-20 2026-02-26 江苏恒瑞医药股份有限公司 一种包含il-36r/il-23结合蛋白的药物组合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
EP1798286B1 (en) 1997-08-01 2011-09-07 Schering Corporation Mammalian cell membrane proteins and related reagents
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CA2499891A1 (en) 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗mdl−1抗体
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 il-22, il-17 및 il-1 패밀리 시토킨의 용도
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EP2473528B1 (en) * 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ang2 항체를 함유하는 안정화된 제형
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
US20180008707A1 (en) 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
US10166993B2 (en) 2015-08-05 2019-01-01 Ford Global Technologies, Llc Customer driving mode for vehicles
EP3601350A1 (en) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
KR20210119407A (ko) 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations

Also Published As

Publication number Publication date
IL286100B2 (en) 2024-12-01
TW202100141A (zh) 2021-01-01
AU2020238676A1 (en) 2021-09-16
JP2022524502A (ja) 2022-05-06
CN113543772A (zh) 2021-10-22
JP7420827B2 (ja) 2024-01-23
BR112021016198A2 (pt) 2021-11-03
US11730812B2 (en) 2023-08-22
US20200282053A1 (en) 2020-09-10
EP3934617A1 (en) 2022-01-12
WO2020185479A1 (en) 2020-09-17
CL2021002331A1 (es) 2022-06-17
IL286100A (en) 2021-10-31
US20230372480A1 (en) 2023-11-23
CA3132917A1 (en) 2020-09-17
PH12021552150A1 (en) 2022-08-15
IL286100B1 (en) 2024-08-01
MX2021010783A (es) 2021-09-30
EA202192405A1 (ru) 2022-01-13
AU2020238676B2 (en) 2025-04-17
JP2024020372A (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
US20230372480A1 (en) Anti-il-36r antibody formulations
AU2021286378B2 (en) Methods of treating inflammatory diseases
US12559551B2 (en) Stabilized formulations containing anti-ANGPTL3 antibodies
CN109078182B (zh) 抗体制剂
CA2924069C (en) Liquid protein formulations containing ionic liquids
TW201343177A (zh) 含抗Ang-2抗體之安定化調配物
TW201601756A (zh) 抗體調配物
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
JP2025519612A (ja) Igf1r抗体
CN111201036A (zh) 包含抗α(V)β(6)抗体的药物组合物和剂量方案
TW202506179A (zh) 含有抗ox40l抗體之醫藥配製物
EA047696B1 (ru) Составы антител против il-36r
KR20230035595A (ko) 항-ctla-4 항체를 함유하는 안정화된 제형
US12472253B2 (en) Activin a antibody formulations and methods of use thereof
EA048605B1 (ru) Стабилизированные составы, содержащие анти-angptl3-антитела
HK40000750B (en) Antibody formulations
HK40000750A (en) Antibody formulations
CN119907685A (zh) 用于抗c1q抗体的制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701